Working… Menu

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03977584
Recruitment Status : Recruiting
First Posted : June 6, 2019
Last Update Posted : November 8, 2021
Banner Alzheimer's Institute
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Hoffmann-La Roche

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : March 31, 2022